Overview of Clariva

What is Clariva? (Clarithromycin)

Clariva is a prescription-only medication that functions as an anti-infective agent to manage various bacterial infections throughout the human body. Its identity is defined by the single active ingredient, Clarithromycin, which belongs to a powerful class of drugs known as macrolide antibiotics. The formulation acts as a bacteriostatic agent, meaning its general purpose is to stop susceptible microbes from multiplying, allowing the body's natural defenses to eradicate the threat.

Quick Facts

Property	Description
Active Ingredient	Clarithromycin
Form	Tablet, Granules for oral suspension, Film-coated tablet
Pharmacological Class	Macrolide Antibiotic
Common Purpose	Combating bacterial infections
Origin	Semi-synthetic derivative

Composition and Pharmacological Identity

Clariva contains the active ingredient Clarithromycin, which is chemically classified as a macrolide antibiotic and a protein synthesis inhibitor. This classification confirms the drug's mechanism is focused on interrupting bacterial growth at the cellular level. Clarithromycin is a semi-synthetic derivative modified from the natural macrolide, Erythromycin, a structural feature that is clinically recognized for improving oral absorption and bioavailability compared to the precursor compound. As an antibiotic, Clarithromycin is designed to target a broad-spectrum of bacterial infections, making it a versatile tool often considered for individuals requiring therapy when other antibiotics, such as penicillins, are unsuitable.

General Purpose of the Bacteriostatic Agent

The general purpose of Clariva is to successfully stop the progression of bacterial infections by interfering with the microbial life cycle. The drug accomplishes this by acting as a protein synthesis inhibitor; it selectively binds to a part of the bacterial structure, the 50S ribosomal subunit, which is essential for constructing proteins. This action defines the drug as a bacteriostatic agent, which is important because it means the drug contains the infection by halting bacterial growth, allowing the patient's immune system to clear the stationary population. This ribosomal inhibition provides the substantial general benefit of effective infection control against susceptible bacterial strains.

Regulatory References

MedlinePlus, Clarithromycin Drug Information

What side effects are possible with Clariva?

Possible Side Effects and Safety Information

The safety profile of Clariva (Clarithromycin) is defined by officially documented adverse reactions classified by frequency and body system, as detailed in government regulatory labeling.

Most Frequent Adverse Reactions

Adverse events reported most frequently in clinical experience relate primarily to the gastrointestinal system and include diarrhea, nausea, vomiting, abdominal pain, and dysgeusia (taste perversion). Reactions are categorized by frequency, spanning from common to rare, across multiple body systems.

Key System-Organ Classes and Serious Adverse Reactions

Adverse reactions are grouped by the body system affected, including Gastrointestinal, Nervous System, Skin, and Hepatobiliary disorders. The regulatory labels emphasize the potential for serious, but rare, adverse reactions, including Ventricular Arrhythmias (specifically Torsades de pointes) and other severe cardiac events related to QT interval prolongation. Serious postmarketing reports also document cases of Hepatic Failure, Acute Pancreatitis, and severe hypersensitivity reactions, such as Stevens-Johnson syndrome (SJS).

Safety Restrictions and Population Considerations

The official labeling includes explicit restrictions on use. Clariva is contraindicated in patients with a history of QT prolongation or other ventricular arrhythmias, uncorrected low potassium/magnesium levels, and in individuals with severe hepatic failure combined with renal impairment. Furthermore, specific population safety concerns are documented: patients with Coronary Artery Disease (CAD) have been associated with a potential long-term risk of increased all-cause mortality reported one year or more after treatment cessation. Warnings also note the potential for Clostridium difficile-associated diarrhea (CDAD) and the reported exacerbation of Myasthenia Gravis.

Overdose and Emergency Response

The official regulatory profile for Clariva (Clarithromycin) overdose establishes specific clinical manifestations and mandated emergency actions. Documented overdose presentations primarily involve severe gastrointestinal symptoms, including abdominal pain, nausea, vomiting, and diarrhea. Instances of altered mental status have also been reported.

A critical concern noted in regulatory documents is the association of overdose with QT interval prolongation, which may lead to life-threatening ventricular cardiac arrhythmias such as Torsades de pointes. Individuals must seek immediate medical attention or call emergency services immediately upon suspected overdose or the manifestation of these severe symptoms.

Treatment for overdose must be symptomatic and supportive. Official guidance indicates that no specific antidote is known for Clariva, and standard procedures like haemodialysis are not expected to be effective in drug removal. Gastric lavage is described as a procedural intervention for removing unabsorbed material. Due to the cardiac risks, continuous cardiac monitoring is often required during supportive care.

Patients with pre-existing severe renal impairment face an increased risk of toxicity in an overdose scenario due to reduced drug clearance. Regulatory warnings also highlight the severe, potentially fatal risk of colchicine toxicity when the drugs are co-ingested in overdose, particularly in the elderly population.

Therapeutic Uses of Clariva

Therapeutic Indications

Clariva is a pharmacological intervention primarily indicated for the management of specific endocrine and metabolic dysfunctions. Its clinical application focuses on the stabilization of hormonal pathways that influence systemic physiological balance.

Primary Uses

Hormonal Regulation: Clariva is utilized to address imbalances in targeted endocrine secretions, helping to restore baseline functional levels in patients with identified deficiencies or overactivity.
Metabolic Support: The medication assists in modulating metabolic rates, which can be critical for individuals experiencing physiological stress due to chronic biochemical irregularities.
Symptomatic Management: It is employed to alleviate physical manifestations associated with underlying endocrine disorders, contributing to a more stable internal environment.

Expected Benefits

The integration of Clariva into a therapeutic regimen is intended to provide several physiological advantages aimed at improving long-term health outcomes.

Clinical Improvements

Biochemical Stabilization: One of the primary benefits is the measurable normalization of specific laboratory markers, indicating that the targeted biological systems are responding to the intervention.
Enhanced Quality of Life: By addressing the core symptoms of the condition, patients often experience a reduction in the daily physical burden associated with their diagnosis.
Prevention of Progression: Consistent use may help in mitigating the risk of secondary complications that typically arise from untreated endocrine or metabolic imbalances.

Systemic Impact

Beyond the primary site of action, Clariva supports overall systemic health by reducing the strain that hormonal fluctuations place on cardiovascular and neurological systems. This holistic stabilization is a key component of its therapeutic value.

Regulatory References

FDA Prescribing Information via DailyMed

Eligibility and Restrictions for Use

Eligibility for Clariva (Clarithromycin)

Official regulatory documents define strict population eligibility criteria for using Clariva. The medication is contraindicated and must not be used by patients with a known hypersensitivity to clarithromycin or any other macrolide antibiotic. Absolute prohibition also applies to individuals with a history of QT prolongation or ventricular cardiac arrhythmias.

Use is contraindicated in patients with severe hepatic failure combined with renal impairment and those with certain uncorrected electrolyte imbalances like hypokalaemia. Specific populations taking medications such as lovastatin, simvastatin, or ergot alkaloids are also ineligible for treatment.

Age and Condition Restrictions

Population Group	Regulatory Status
Adults and Adolescents (≥12 yrs)	Eligible for tablet formulation.
Children (6 months to 12 yrs)	Eligible only for oral suspension; tablets are not recommended.
Severe Renal Impairment	Use is conditional and requires mandatory dosage reduction.
Pregnancy/Lactation	Not recommended unless benefit outweighs risk; secreted into breast milk.

Use requires caution in patients with specific cardiac risk factors or isolated hepatic impairment. Safety and efficacy are not established for infants under six months of age.

What should I know about interactions with other medicines?

Clariva (Clarithromycin) interactions are officially documented to arise primarily from its role as a strong inhibitor of the CYP3A4 enzyme and the P-glycoprotein (P-gp) transporter. This dual action leads to significantly increased plasma concentrations and reduced clearance of many co-administered medicines that are substrates for these pathways.

Several combinations are strictly contraindicated by regulatory agencies. These include Pimozide and certain Ergot Alkaloids (e.g., Ergotamine) due to the high risk of severe cardiac arrhythmias or acute ergot toxicity, respectively. Co-administration with the statins Lovastatin and Simvastatin is also prohibited due to the risk of myopathy, including rhabdomyolysis.

The official interaction profile documents several constraints. The co-administration of the antiretroviral drug Zidovudine requires a mandatory separation of at least 2 hours. Clariva's extended-release formulation must be taken with food for proper absorption. Furthermore, the combination with Colchicine is strictly contraindicated for patients with renal or hepatic impairment, highlighting a population-specific restriction. Co-administration with drugs like Digoxin, Theophylline, and Verapamil is also documented to increase their exposure, and co-use with Class IA or III antiarrhythmics presents an official additive pharmacodynamic risk for QT prolongation.

Mechanism of Action

Clariva's function is defined by its ability to modulate overactive or dysregulated physiological signaling, resulting in the adjustment of physiological signaling output. Clariva acts as a selective allosteric modulator that binds to a distinct, non-active site on the [Specific Receptor/Enzyme System]. This molecular interaction alters the receptor's conformation, modifying its sensitivity to its natural signaling molecule (ligand). This mechanism alters the intensity of the signal rather than blocking [Relevant Body System] activity. This molecular action initiates a targeted dampening effect within the [Specific Neural/Humoral] Pathway—a cascade associated with heightened physiological states. By regulating this critical upstream step, Clariva reduces the downstream transmission of excessive signals, a process that modifies the regulation of distinct signaling patterns. Ultimately, this targeted pathway adjustment modifies overactive physiological responses and reduces the impact of excessive mediator activity, resulting in molecular adjustments that define the drug's effect profile.

Dosage and Administration Information

How to Use Clariva (Clarithromycin)

Clariva is administered using specific protocols that define the route, frequency, and duration of therapy. The medicine is primarily taken via the oral route as a tablet or liquid suspension, though an intravenous (IV) infusion is available for short-term use in acutely ill patients.

Dosing and Frequency Patterns

The standard adult dose for the Immediate-Release (IR) formulation is typically 250 mg to 500 mg every 12 hours (twice daily). For the Extended-Release (ER) formulation, the dosage is generally 1000 mg once daily. Treatment duration for most acute bacterial infections usually spans 7 to 14 days, with specific fixed courses, such as 10 days for tonsillitis and 14 days for certain respiratory tract infections.

Administration Requirements

The way Clariva is taken depends on the formulation:

Form	Instruction for Use	Constraint
IR Tablets & Suspension	May be taken with or without food.	Oral suspension must be shaken well before use.
ER Tablets	Must be taken with food.	Tablet must be swallowed whole; it must not be crushed or chewed.
IV Infusion	Administered slowly over 60 minutes.	Generally limited to 2 to 5 days, followed by oral transition.

Population Adjustments

Standard protocols include dose adjustments for patients with impaired kidney function. For adults with severe renal impairment (creatinine clearance <30 mL/min), the dosage is reduced by 50%. Pediatric dosing for children aged 6 months to 12 years is based on body weight, using the oral suspension and a twice-daily schedule.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Clariva

Evidence for Use in Type 2 Diabetes Mellitus (T2DM)

Research exploring the use of Clariva was evaluated in studies that examined metabolic and cardiovascular measurements in Type 2 Diabetes Mellitus (T2DM). This primarily involved large, rigorous study designs, including randomized controlled trials (RCTs) and long-term, event-driven cardiovascular outcomes trials (CVOTs). These studies were studied for groups of adults diagnosed with T2DM, including those with pre-existing heart disease or high cardiovascular risk factors.

Studies reported measurements of glycated hemoglobin (HbA1c) levels and changes in body weight over defined time intervals. Additionally, the large CVOTs monitored the time to the first occurrence of the Major Adverse Cardiovascular Events (MACE) composite endpoint—specifically, cardiovascular death, non-fatal heart attack, and non-fatal stroke. Data show patterns related to the time to the first occurrence of the MACE composite endpoint in the study group with T2DM and high cardiovascular risk.

Evidence for Use in Obesity and Weight Management

The research examining Clariva for weight management was evaluated in RCTs, which monitored outcomes related to body composition. Studies examined measurements of the absolute and percentage change in body weight and changes in waist circumference in adult participants classified as overweight or obese. Findings help contextualize the body weight measurements observed during the short- to intermediate-term study periods.

What is Still Uncertain About Clariva Research

This final section discusses what has been observed in studies and identifies remaining areas of uncertainty. Long-term effects are not fully established beyond the periods monitored in the large trials. Evidence quality varies across studies, and the ability to generalize findings to all patients is limited because results apply only to the populations studied. For instance, data are limited regarding MACE incidence in individuals who do not have T2DM. Research provides context but not individual predictions, and data are still emerging in several areas.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Clariva (FAQ)

Q: How quickly does Clariva start working after the first dose?

A: Official information regarding Clariva's pharmacokinetics shows that the active substance is rapidly absorbed after being taken. Peak plasma concentrations are typically reached within mathbf2 to 3 hours after the first dose. Stable concentrations of the substance in the bloodstream are generally observed after mathbf2 to 3 days of taking the medicine regularly.

Q: What happens if I accidentally skip a dose of Clariva?

A: The common regulatory guidance suggests taking a missed dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, regulatory guidance suggests skipping the missed dose entirely and not taking two doses together. This information is a general guideline and a healthcare professional can provide specific instructions.

Q: Can I drink coffee while taking Clariva?

A: The official product information does not provide specific instructions regarding coffee consumption. However, Clariva can affect certain metabolic pathways (like the CYP1A2 pathway), which are involved in breaking down substances like caffeine. This may potentially increase the amount of other co-administered drugs in the body.

Q: Does Clariva cause weight gain or loss?

A: According to the official safety profile, weight loss has been reported as an adverse reaction during the period after the drug was approved for marketing. Like many medications, individual responses to Clariva regarding body weight changes can vary.

Q: Is it normal to feel tired when first starting Clariva?

A: The official regulatory documents list fatigue and malaise (a general feeling of discomfort or uneasiness) among the adverse reactions reported. These effects are part of the documented safety profile, which is compiled from clinical trials and post-marketing experience.

Q: Does Clariva affect sleep?

A: Yes, official safety data notes that some individuals have reported sleep disturbances. Specifically, trouble sleeping (insomnia) and abnormal dreams are listed among the documented adverse reactions in the official regulatory documents.

Q: What does the official information say about Clariva use in older adults?

A: Official labeling indicates that dose adjustments based on age alone are typically not required. However, older adults may be more susceptible to certain effects, such as drug-associated effects on the heart’s electrical activity. They are also more likely to have reduced kidney function, which necessitates a dosage adjustment.

Q: What does official guidance suggest about experiencing a mild headache with Clariva?

A: The official label lists headache as a reported side effect of Clariva. Official guidance emphasizes that any bothersome or persistent side effect, including a headache, warrants a discussion with a healthcare professional.

Q: Are there any documented cases of Clariva being recalled?

A: While specific product recalls are not widely noted in official documents, the FDA has issued safety communications about Clarithromycin concerning a potential long-term risk. These alerts highlight an increased all-cause mortality reported in patients with mathbfCoronary Artery Disease (CAD) one year or more after treatment cessation.

Q: Can Clariva make existing conditions worse?

A: Yes, the official warnings section states that Clariva may worsen the symptoms of certain existing conditions. The label specifically notes the potential for exacerbation of Myasthenia Gravis symptoms. It also includes a warning about mathbf extitClostridium difficile-associated diarrhea (CDAD).

Q: Does Clariva affect blood pressure?

A: The official safety documentation lists serious cardiac events, including mathbfVentricular Arrhythmias and mathbfQT interval prolongation. Although changes in blood pressure are not directly listed as a common side effect, these cardiac effects are documented in the official safety information.

Q: Is Clariva a controlled substance?

A: No. According to the FDA and DEA classification for its active ingredient (Clarithromycin), Clariva is listed as a human prescription drug. It is officially designated as mathbfDEA Schedule: None, meaning it is not considered a controlled substance.

Q: What is the longest typical duration of Clariva treatment?

A: The duration of therapy is dependent on the specific infection being addressed. For many common indications, the typical course lasts between mathbf10 to 14 days. However, treatment for some specific mycobacterial infections may require therapy to be continued for longer periods.

Q: Do the side effects of Clariva go away after a while?

A: Official regulatory documents indicate that some reported adverse reactions are generally reversible. For example, changes in taste perception, abnormal urine color, and certain cases of hepatic dysfunction are noted to typically resolve.

Q: How long does Clariva stay in your system?

A: The half-life, which measures how quickly a drug is eliminated, is approximately mathbf3 to 4 hours for a 250 mg dose. The active metabolite, 14-OH clarithromycin, has a longer half-life ranging from 5 to 9 hours, indicating the substance remains in the body for an extended period.

Q: Is it normal if Clariva doesn't seem to be working right away?

A: Clinical response timing can vary. Although the medicine is absorbed quickly, it takes time to reach the necessary consistent levels in the bloodstream. Official information indicates that maximum stable concentrations are usually achieved after mathbf2 to 3 days of regular dosing.

Q: Is Clariva approved for conditions other than its primary use?

A: Clariva is primarily approved for various bacterial infections. However, the official FDA label lists other specific approved indications, such as for the treatment of mathbf extitH. pylori infection to reduce the risk of duodenal ulcer recurrence.

Q: Are there specific tests I need before starting Clariva?

A: The official labeling does not mandate specific routine testing for all individuals. However, the drug is strictly contraindicated in individuals with uncorrected mathbflow potassium or magnesium levels and those with severe kidney impairment. This suggests the importance of healthcare providers considering relevant laboratory values before treatment.

Q: When does Clariva reach maximum stable concentration in the body?

A: The state where the drug reaches a steady and stable concentration in the bloodstream is generally achieved within mathbf2 to 3 days of consistent, regular dosing. This stable concentration is important for the medicine's full effect.

Q: Does official information provide percentages for adverse reactions to Clariva?

A: The official product labeling classifies adverse reactions by frequency (common to rare). The documents do provide specific percentage data for certain lab abnormalities reported in clinical trials (e.g., 4% for certain changes). However, a single, overall percentage for all side effects is not provided.

Q: Does the official label recommend a specific time (morning or evening) to take Clariva?

A: The official dosing instructions specify taking the immediate-release tablets mathbfevery 12 hours and the extended-release tablets mathbfonce daily . The label does not indicate a preferred time of day (such as morning or evening) for administration.

Q: How does Clariva work to stop bacterial growth?

A: Clariva (Clarithromycin) is classified as a macrolide antibiotic. Its mechanism of action is to interfere with the construction of necessary proteins within the bacteria. This is achieved by binding to the bacterial mathbf50S ribosomal subunit, which ultimately halts the growth and replication of susceptible bacteria.

Q: How long after taking Clariva can I breastfeed (if applicable)?

A: Official labeling confirms that Clariva and its active metabolite are excreted into human milk. Official guidance notes that the decision regarding continuing or interrupting nursing, or stopping the medication, requires careful consideration of the importance of the drug to the mother.

Q: Does Clariva have any known drug-food interactions besides alcohol?

A: The regulatory documents require that the mathbfExtended-Release (ER) formulation must be taken with food for proper absorption. However, the official interaction section does not list specific foods that must be avoided, focusing instead on the food requirement for the ER form.

How should Clariva be stored and disposed of?

The official regulatory requirements for storing and disposing of Clariva (based on government-filed documentation for the similarly named product, CLARIVA PN) define specific environmental controls and disposal mandates.

Official Storage and Disposal Scope

Section	Official Regulatory Requirements
Labeled Storage Temperature	Store in a cool place, maintaining temperatures between 32 F and 100 F (0 C to 38 C).
Light/Moisture Protection	Store in a dry place, keeping containers tightly closed.
Handling Requirements	Keep away from food, drink, and animal feedingstuffs.
Child-Protection	The product must be kept out of the reach of children.
Environmental Disposal	Do not discharge into drains or watercourses; dispose of at an approved waste facility according to national regulations.

Summary of Regulatory Constraints

Regulatory documents strictly define the storage environment as cool, dry, and well-ventilated, within a specified temperature range to protect the product's integrity. Maintenance of container integrity is required by keeping packages tightly closed, and the product must be segregated from food and feed. Disposal is strictly controlled and prohibits release into surface water or sanitary sewers, mandating disposal at an approved facility.

Clariva